Enveda Raises $311M Series E at $2B Valuation — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Enveda, a Colorado-based biotech startup, raised a $311 million Series E round at a $2 billion valuation, per TechCrunch.
- The $2 billion valuation represents double Enveda's value from one year earlier, reflecting rapid appreciation for the company's AI-driven approach to sourcing drug candidates from the natural world.
Why it matters: Enveda's valuation doubling to $2B in a single year puts it among the fastest-appreciating AI-bio startups, and the $311M Series E gives the company a sizable capital runway to advance its nature-derived drug-discovery pipeline toward clinical development.
Ask SkimNews
